Abstract
Objective: To assess olfactory function in individuals with classical (infratentorial) superficial siderosis (iSS)
Background: iSS is a rare but potentially disabling and progressive neurological disorder that commonly involves auditory and vestibular neural pathways. Olfactory nerve function may also be affected but dedicated studies assessing this in iSS are lacking.
Design/Methods: Ethics approval was granted. Eleven participants with a known diagnosis of iSS and no prior symptoms or history of COVID-19, were provided with the 40-item (British version) University of Pennsylvania Smell Identification Test (UPSIT) kits by post. The scores (40 as maximum best) were graded as normal, microsmia (mild/moderate/severe) and anosmia, as compared with age- and gender-matched norms; percentile values were obtained. Smoking status was determined; pack-years, years since smoking-cessation and disease duration (from presumed causative event) were calculated.
Results: Ten participants completed the test. The mean (±standard deviation, SD) age was 52.5(±14.5) years; 2 participants (20%) were females; 6 participants (60%) never smoked; 1 participant (10%) was a current smoker. The mean(±SD) UPSIT score was 25.5(±7.8), with no difference between males/females (t(10)=−1.528, p=0.165). The mean(±SD) disease duration (n=9) was 23.2(±11.4) years. The UPSIT scores were statistically significantly lower than age-/gender-matched norms (t(9)=4.016; p=0.003), and below the 30th centile for all participants (<10th percentile for 4 (40%); in 10–20th percentile for 5 (50%); in 20–30th percentile for 1 (10%)). Six participants (60%) had anosmia or moderate microsmia and 4 (40%) had mild microsmia. There was no correlation (as assessed by Kendall’s tau-b, Tb) (p>0.05) between the UPSIT scores and: age (Tb(10)=−.114); years since smoking-cessation (Tb(4)=.333), pack-years (Tb(4)=−.333), or disease duration (Tb(9)=.310).
Conclusions: We report a novel quantitative assessment of the prevalence of olfactory dysfunction in iSS. Given its high prevalence, olfactory dysfunction may be another key feature of the iSS clinical syndrome that is currently under-investigated but should routinely be assessed.
Disclosure: Dr. Kharytaniuk has received research support from NIHR UCLH BRC Deafness and Hearing Problems Theme . Dr. Pavlou has nothing to disclose. Prof. Bamiou has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
